Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 2

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 2
---
 or the Securities Act, thus we are eligible
for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate governance rules.

NewGenIvf Group Limited (“NewGenIvf,”
“Company,” “our,” “we,” or “us”) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited), Asia (Hong Kong,
Thailand, Kyrgyzstan, and the Kingdom of Cambodia), and in the United States. Under this holding company structure, investors are purchasing
equity interests in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands
and Asian operating subsidiaries. Substantially all of NewGenIvf’s operations and assets are based in Thailand, Cambodia and Kyrgyzstan.
As a result, its businesses and operations are subject to the changing economic conditions prevailing from time to time in such countries.

On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the “Panel”) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at an oral hearing on January 28, 2025 (the “Hearing”). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with
the Nasdaq Stock Market’s continued listing requirements, subject to meeting specific compliance criteria within designated timeframes.
As of the date of this prospectus, in accordance with the Panel’s extension, the Company has already made progress on its compliance
plan, including carrying out a 1-for-20 reverse stock split of its issued and unissued shares which was effected on February 11, 2025.
The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025, the
Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company’s securities had been
at $1.00 per share or greater for 10 consecutive business